Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$41.57 USD
-0.88 (-2.07%)
Updated Aug 2, 2024 04:00 PM ET
3-Hold of 5 3
A Value B Growth F Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AMPH 41.57 -0.88(-2.07%)
Will AMPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AMPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMPH
HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2024 EPS View
UnitedHealth Group (UNH) Q2 Earnings Beat on Strong Optum Unit
AMPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Amphastar (AMPH) is Poised to Beat Earnings Estimates Again
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
Implied Volatility Surging for Amphastar (AMPH) Stock Options
Other News for AMPH
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024
Insider Sale: CFO, EVP & Treasurer William Peters Sells Shares of Amphastar Pharmaceuticals ...
Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Verona Pharma (VRNA) and Henry Schein (HSIC)
Piper Sandler Keeps Their Buy Rating on Amphastar Pharmaceuticals (AMPH)
Amphastar management to meet with Piper Sandler